ALS Drug Relyvrio Fails Key Clinical Trial, May Be Pulled from Market

Amylyx Pharmaceuticals to consult with FDA and ALS community after disappointing trial results; stock plunges over 83%.

Amylyx Pharmaceuticals announced that its ALS drug Relyvrio failed a large clinical trial, potentially leading to its withdrawal from the market.
Relyvrio did not show significant benefits in improving ALS patients' functional scale or quality of life over a placebo.
The FDA had approved Relyvrio in September 2022 despite initial skepticism, influenced by ALS patient advocacy and a promise of further testing.
Amylyx's stock plummeted more than 83% following the announcement of the trial results.
The company plans to discuss the future of Relyvrio with regulatory authorities and the ALS community over the next eight weeks.